Full-Time

Virology HIV Community MSL

Regional Medical Scientific Associate Director, Multiple Teams

Posted on 8/5/2026

Deadline 8/15/26
Merck

Merck

10,001+ employees

Pharmaceutical company developing medicines and vaccines

Compensation Overview

$173.2k - $272.6k/yr

+ Annual bonus + Long-term incentive

No H1B Sponsorship

Orlando, FL, USA + 4 more

More locations: Tampa, FL, USA | Miami, FL, USA | Florida, USA | Fort Lauderdale, FL, USA

Remote

Must reside in the coverage region; travel is required up to 75%.

PhD

Category
Medical, Clinical & Veterinary (1)
Biology & Biotech (1)
Required Skills
Microsoft Office
FDA Regulations
Word/Pages/Docs
HIPAA
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Merck

See people who can refer or advise you

Requirements
  • A doctorate degree or advanced practice professional such as a PhD, PharmD, NP, or PA relevant to Virology and the requirements of the position.
  • A minimum of 3 years of prior experience in a biotechnology, pharmaceutical, or healthcare environment.
  • A minimum of 3 years of clinical and/or research experience in Virology, HIV, or a related therapeutic area.
  • Excellent interpersonal, communication, networking, and presentation skills.
  • Ability to travel up to 50% of the time overnight and reside in the coverage region.
  • Deep therapeutic competency and current awareness of trends and new information in Virology.
  • Ability to network and partner with important external scientific leaders and healthcare providers.
  • Ability to consolidate and understand complex data sets, plan and/or execute data analyses, summarize or synthesize data, and objectively interpret results.
  • Knowledge of national and society treatment guidelines, clinical research processes, FDA regulations, OIG, HIPAA, and other ethical guidelines, laws, and regulations relevant to the pharmaceutical industry.
  • Ability to organize, prioritize, and work effectively in a constantly changing environment.
Responsibilities
  • Work within the Medical Affairs organization to identify, establish, and manage collaborative professional relationships with community-based scientific leaders and healthcare providers.
  • Conduct peer-level scientific discussions and maintain a reliable presence so scientific leaders have a Medical Affairs contact within the company.
  • Engage in proactive non-product discussions regarding scientific issues to understand real-world prevention gaps, persistent disparities, and barriers to uptake across care settings.
  • Facilitate appropriate scientific exchange of information with scientific leaders, including integrating scientific knowledge with actionable insights to inform company research, development, and strategies.
  • Communicate external stakeholder opinions, insights, and feedback on new data, clinical trends, and the evolving HIV treatment and prevention landscape to Medical Affairs headquarters teams.
  • Represent Research and Development at scientific meetings and congresses to understand consumer sentiment and contribute to Research and Development debriefs, insight discussions, and post-congress reports.
  • Develop and execute territory plans aligned with the global Virology strategy.
  • Support data-generation activities when requested by Research and Development leadership, including the company's Investigator Study Program.
  • Identify potential investigators for participation in Phase II–IV clinical development programs and provide scientific support for Research and Development-sponsored trials as needed.
  • Demonstrate and maintain in-depth knowledge of the assigned disease and therapeutic areas through educational efforts.
  • Comply with all company policies and applicable laws, regulations, and ethical standards.
Desired Qualifications
  • Awareness of the unmet needs and implementation barriers of priority populations receiving services within community-based and non-medical spaces.
  • Prior working experience within the coverage region and established relationships with HIV community stakeholders, especially in HIV prevention.
  • Demonstrable effective leadership skills.
  • Strong working knowledge of Microsoft Office Suite, including Word, PowerPoint, and Excel.

Merck is a global healthcare company that develops medicines, vaccines, and animal health products. It advances long-term health by conducting research and development to create new treatments for diseases such as cardiovascular disease, diabetes, and cancer, then brings these medicines to patients, healthcare professionals, and institutions worldwide. The company’s products work by undergoing scientific discovery, clinical testing, and regulatory approval before being manufactured and sold or distributed through patient assistance programs. What sets Merck apart is its large, diversified portfolio across human medicines, vaccines, and animal health, along with a strong emphasis on R&D, global reach, and support services like Merck Connect and Merck Manuals that provide professional resources. Merck’s goal is to tackle major health threats by applying science to discover and deliver therapies that improve patient outcomes and public health across the globe.

Company Size

10,001+

Company Stage

IPO

Headquarters

Kenilworth, Illinois

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck raised 2026 revenue guidance to $66.3 billion-$67.3 billion after Q2 strength.
  • FDA approvals for KEYTRUDA QLEX and ccRCC expand near-term sales and indication breadth.
  • The Evaxion AI vaccine stake and licensing deepen Merck's next-generation discovery pipeline.

What critics are saying

  • Keytruda biosimilar competition begins December 2028, threatening Merck's largest revenue engine.
  • Bridion loses U.S. exclusivity in July 2026, and Januvia/Janumet already face generic erosion.
  • A failed Keytruda replacement would leave Merck overexposed as oncology patent protection cracks.

What makes Merck unique

  • Keytruda/QLEX dominates oncology; Q2 2026 sales hit $8.4 billion.
  • INTerpath-001 made Merck the first Phase 3 winner for individualized mRNA cancer vaccines.
  • The Merck-Moderna pairing combines blockbuster commercialization, global trials, and rapid regulatory reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-20%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Aug 23rd, 2026
Merck (MRK) Takes An AI Vaccine Stake And Expands Its Discovery Playbook

Merck (NYSE: MRK) disclosed an equity stake in Evaxion A/S tied to an AI powered vaccine program centered on candidate EVX-B3. The company in licensed EVX-B3, an AI guided vaccine candidate, as part of its push into AI driven vaccine discovery. The move extends Merck's use of artificial intelligence beyond its existing focus on traditional pharmaceuticals and mRNA oncology research. Readers who want more ideas at the intersection of healthcare and artificial intelligence may also want to...

Yahoo Finance
Aug 21st, 2026
Musk backs mRNA potential as Moderna and Merck trial shows cancer vaccine breakthrough

Elon Musk said mRNA technology has "tremendous promise for curing diseases" despite what he termed its "obvious misuse during Covid". The Tesla chief executive officer suggested artificial RNA essentially makes curing diseases a software problem. Musk's comments came as Moderna and Merck announced positive Phase 3 results for an individualised mRNA cancer vaccine. The treatment showed significant improvement in recurrence-free and metastasis-free survival in melanoma patients when combined with Merck's Keytruda. This marks the first successful late-stage trial of its kind. Musk has previously promoted artificial intelligence as a path to transforming healthcare. In June, he said advances in synthetic RNA could potentially "cure almost anything".

Yahoo Finance
Aug 20th, 2026
Merck takes $3.8M stake in AI vaccine developer Evaxion after licensing bacterial candidate

Merck & Company disclosed holding 1,214,126 shares of AI immunology firm Evaxion A/S in a regulatory filing on 10 August. Evaxion shares rose 2% to $3.17 following the announcement. The position follows Merck's September 2025 decision to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate targeting an undisclosed bacterial pathogen. Argus raised its price target on Merck from $130 to $145 on 11 August, citing regulatory approvals and pipeline depth. Merck reported Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA. Evaxion reported zero revenue in Q1 2026 with a net loss of $3.6 million. Hedge fund holdings in Merck fell from 100 funds in Q4 2025 to 98 in Q1 2026.

Yahoo Finance
Aug 20th, 2026
Merck dips 0.5% after 12.6% surge on positive cancer-vaccine trial results

Merck shares dipped approximately 0.5% to $151.39 on Thursday following a 12.6% surge the previous day, reaching a record close. The pharmaceutical company's stock jumped after positive results from a Phase 3 trial testing a personalized melanoma vaccine developed with Moderna. The 1,137-patient study met its primary endpoints for recurrence-free survival and distant-metastasis-free survival. The trial compared Keytruda alone against Keytruda plus intismeran in patients with surgically removed high-risk melanoma, with no new safety concerns identified. Merck and Moderna are also testing the vaccine platform in lung, bladder, kidney, pancreatic and stomach cancers. Keytruda generated approximately $8.4 billion in second-quarter sales, representing roughly half of Merck's revenue. The stock now trades 26.28% above its estimated fair value of $119.88.

Yahoo Finance
Aug 20th, 2026
Merck surges 12.6% as personalised cancer vaccine beats standard melanoma treatment

Merck announced its personalised cancer vaccine combined with immunotherapy Keytruda significantly improved outcomes for melanoma patients in a Phase 3 trial. The 135-year-old drugmaker's stock jumped 12.6% on 19 August following the news. The trial tested intismeran autogene, developed with Moderna, alongside Keytruda in patients with surgically removed stage IIB through IV melanoma. Patients receiving the combination stayed cancer-free longer and experienced delayed cancer spread compared to those on Keytruda alone. The treatment uses mRNA technology tailored to each patient's tumour mutations, training the immune system to target up to 34 specific genetic changes. It marks the first time an individualised cancer vaccine has shown positive results in late-stage testing. Keytruda generated $8.4 billion in second-quarter sales, representing over 50% of Merck's quarterly revenue.

INACTIVE